NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.
- The poster presentation highlights LNBC74’s promising preclinical safety and anti-tumor activity.
- The presentation includes data demonstrating LNCB74’s high affinity and specificity for human B7-H4, a protein highly expressed on a range of solid tumors including breast, ovarian and endometrial cancers.
- LNCB74 was shown to specifically bind to B7-H4 expressing tumor cells and was rapidly internalized in a target-dependent manner.
- “These data underscore that LNCB74 is a promising candidate for the treatment of a variety of solid tumor indications.